|1.||Lu, Zheng-Rong: 5 articles (02/2010 - 04/2005)|
|2.||Jeong, Eun-Kee: 4 articles (02/2010 - 05/2009)|
|3.||Parker, Dennis L: 4 articles (02/2010 - 04/2005)|
|4.||Gibrat, C: 3 articles (10/2015 - 02/2010)|
|5.||Cicchetti, F: 3 articles (10/2015 - 02/2010)|
|6.||Kim, In-Gyu: 3 articles (03/2015 - 12/2004)|
|7.||Tzang, Bor-Show: 3 articles (04/2013 - 02/2007)|
|8.||Huang, Chih-Yang: 3 articles (04/2013 - 02/2007)|
|9.||Hsu, Tsai-Ching: 3 articles (04/2013 - 02/2007)|
|10.||Leavitt, Blair R: 3 articles (12/2011 - 08/2005)|
01/28/2010 - "Taken together, the present findings suggest that cystamine may be an effective sensitizer of TRAIL-induced apoptosis in cancer cells expressing high levels of TG2."
02/01/2010 - "The efficacy of polydisulfide-based biodegradable macromolecular Gd(III) complexes, Gd-DTPA cystamine copolymers (GDCC), for assessing tumor microvascular characteristics and monitoring antiangiogenesis therapy was investigated in a mouse model using dynamic contrast-enhanced MRI (DCE-MRI). "
02/01/2010 - "Noninvasive evaluation of antiangiogenic effect in a mouse tumor model by DCE-MRI with Gd-DTPA cystamine copolymers."
04/01/1985 - "We have examined the pharmacological characteristics of three dinitrosated isomers of N,N'-bis[N(2-chloroethyl)-N-carbamoyl]cystamine [CNCC-(D), 1C1G1325] differing in the relative positions of the nitroso substituents [CNCC-(C), (1,1' dinitroso); CNCC-(S), 3,3' dinitroso); and CNCC-(M), (1,3'-dinitroso)] and which were designed to be subject to preferential bioreductive activation in hypoxic tumors. "
12/01/1970 - "[Effect of cystamine on cytogenetic changes in bone marrow cells and lymphocytes of the peripheral blood in patients with bronchial cancer treated with thio-TEPA]."
|2.||Huntington Disease (Huntington's Disease)
06/01/2006 - "The protective effects of cystamine in the R6/2 Huntington's disease mouse involve mechanisms other than the inhibition of tissue transglutaminase."
10/01/2015 - "The neuroprotective properties of cystamine identified in pre-clinical studies have fast-tracked this compound to clinical trials in Huntington's disease, showing tolerability and benefits on motor symptoms. "
12/01/2011 - "Cystamine has demonstrated neuroprotective activity in a variety of studies, and is currently being evaluated in a human clinical trial in Huntington's disease (HD). "
10/01/2005 - "Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease."
08/01/2005 - "Cystamine is beneficial to Huntington disease (HD) transgenic mice. "
|3.||Radiation Injuries (Radiation Sickness)
07/01/1990 - "Cystamine given to rats prior to irradiation with a dose of 8 Gy (LD77/30) ameliorates significantly the severity of radiation sickness and restores spontaneous motor activity by the time of clinical recovery. "
08/01/1960 - "A trial of cystamine in radiation sickness."
05/01/1985 - "The polydeoxyribonucleotide (PDN) level in leukocytes of peripheral blood of rats treated with cystamine adequately reflects the severity and outcome of radiation sickness. "
01/01/1981 - "[Protein metabolic indices in radiation sickness and the administration of cystamine]."
01/01/1977 - "Experiments were performed on the third day after the administration of cystamine, since the author's previous investigations showed that the protective action of cystamine in radiation sickness was strongest at this time. "
|4.||Parkinson Disease (Parkinson's Disease)
06/01/2006 - "These results provide strong evidence for neuroprotective properties of cystamine in this animal model of Parkinson's disease."
09/01/2010 - "Cystamine has shown significant neuroprotective properties in preclinical studies of Parkinson's disease (PD) and Huntington's disease (HD). "
10/01/2015 - "We tested whether cystamine could have such properties in a Parkinson's disease murine model and now provide evidence that it can not only prevent the neurodegenerative process but also can reverse motor impairments created by a 6-hydroxydopamine lesion 3weeks post-surgery. "
10/01/2015 - "Cystamine/cysteamine rescues the dopaminergic system and shows neurorestorative properties in an animal model of Parkinson's disease."
02/01/2010 - "Taken together, these results strengthen the neuroprotective potential of cystamine in the treatment of Parkinson's disease and point towards the up-regulation of BDNF as an important mechanism of action."
|5.||Duodenal Ulcer (Curling's Ulcer)
01/01/1984 - "Immunohistochemistry was used to study the changes in the number of G cells in the antral part of the stomach of rats (40 animals) with cystamine-induced duodenal ulcer treated with beta-endorphine. "
01/01/1985 - "It has been established that the optimal dose (10 micrograms/kg) of dalargin is effective in preventing ulceration in the cystamine duodenal ulcer rat model and the development of stomach erosive lesions in immobilization stress, reducing the degree of liver degeneration in CCl4 poisoning, etc. With an increase of the dose of dalargin the effect "escapes". "
|2.||Gadolinium DTPA (Magnevist)
|3.||5-Methoxytryptamine (5 Methoxytryptamine)
|6.||Carbon Tetrachloride (Tetrachloromethane)
|7.||Messenger RNA (mRNA)
|9.||Tissue Inhibitor of Metalloproteinase-2
|10.||Tissue Inhibitor of Metalloproteinases (TIMP)
|2.||Investigational Therapies (Experimental Therapy)
|3.||Heterologous Transplantation (Xenotransplantation)